Great Point Partners LLC Increases Position in Ptc Therapeutics INC (PTCT)

PTC Therapeutics, Inc. (NASDAQ:PTCT) LogoInvestors sentiment decreased to 1.07 in Q2 2019. Its down 0.99, from 2.06 in 2019Q1. It is negative, as 24 investors sold PTCT shares while 49 reduced holdings. 27 funds opened positions while 51 raised stakes. 53.17 million shares or 3.76% less from 55.24 million shares in 2019Q1 were reported. Rhumbline Advisers holds 0.01% or 79,765 shares. Rafferty Asset Ltd Com has 0.08% invested in PTC Therapeutics, Inc. (NASDAQ:PTCT). Elk Creek Prns Ltd Llc accumulated 290,150 shares. Moreover, Parametric Associates Ltd Liability Co has 0% invested in PTC Therapeutics, Inc. (NASDAQ:PTCT) for 33,708 shares. 684,000 are held by Avoro Cap Advsr. Amalgamated National Bank & Trust has 10,275 shares for 0.01% of their portfolio. 95,765 are owned by Swiss Retail Bank. Atika Mngmt Limited Liability accumulated 75,000 shares or 0.66% of the stock. Pictet Asset Mgmt Ltd invested 0.11% of its portfolio in PTC Therapeutics, Inc. (NASDAQ:PTCT). Neuberger Berman Grp Incorporated Ltd Company reported 0% stake. 87,702 were reported by California Pub Employees Retirement Systems. 80,000 are owned by Jefferies Group Inc Lc. 14,700 are held by Strs Ohio. Wells Fargo Comm Mn has invested 0% of its portfolio in PTC Therapeutics, Inc. (NASDAQ:PTCT). Daiwa Gp Inc holds 0% or 365 shares.

Great Point Partners Llc increased its stake in Ptc Therapeutics Inc. (PTCT) by 8.83% based on its latest 2019Q2 regulatory filing with the SEC. Great Point Partners Llc bought 160,125 shares as the company’s stock rose 32.70% . The hedge fund held 1.97 million shares of the health care company at the end of 2019Q2, valued at $88.85B, up from 1.81 million at the end of the previous reported quarter. Great Point Partners Llc who had been investing in Ptc Therapeutics Inc. for a number of months, seems to be bullish on the $2.55B market cap company. The stock increased 0.21% or $0.09 during the last trading session, reaching $43.23. About 134,412 shares traded. PTC Therapeutics, Inc. (NASDAQ:PTCT) has risen 30.72% since September 13, 2018 and is uptrending. It has outperformed by 30.72% the S&P500.

Great Point Partners Llc, which manages about $935.83M and $900.81B US Long portfolio, decreased its stake in Iovance Biotherapetuics Inc. (Call) by 5.37M shares to 200,000 shares, valued at $4.90 billion in 2019Q2, according to the filing. It also reduced its holding in Zafgen Inc. (NASDAQ:ZFGN) by 899,680 shares in the quarter, leaving it with 2.21M shares, and cut its stake in Acadia Pharmaceuticals Inc. (NASDAQ:ACAD).

More notable recent PTC Therapeutics, Inc. (NASDAQ:PTCT) news were published by: which released: “Notable Monday Option Activity: GS, GBT, PTCT – Nasdaq” on April 22, 2019, also with their article: “Analysts Estimate PTC Therapeutics (PTCT) to Report a Decline in Earnings: What to Look Out for – Nasdaq” published on April 25, 2019, published: “PTC Therapeutics: Opportunity After Secondary Offering? – Seeking Alpha” on January 25, 2019. More interesting news about PTC Therapeutics, Inc. (NASDAQ:PTCT) were released by: and their article: “Should You Worry About PTC Therapeutics, Inc.’s (NASDAQ:PTCT) CEO Pay Cheque? – Yahoo Finance” published on July 19, 2019 as well as‘s news article titled: “PTC Therapeutics Q2 Translarna sales up 21% – Seeking Alpha” with publication date: August 06, 2019.

PTC Therapeutics, Inc. (NASDAQ:PTCT) Ratings Coverage

Among 2 analysts covering PTC Therapeutics (NASDAQ:PTCT), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. PTC Therapeutics has $48 highest and $40 lowest target. $43.67’s average target is 1.02% above currents $43.23 stock price. PTC Therapeutics had 3 analyst reports since March 19, 2019 according to SRatingsIntel. The stock of PTC Therapeutics, Inc. (NASDAQ:PTCT) earned “Buy” rating by RBC Capital Markets on Tuesday, March 19.

PTC Therapeutics, Inc. (NASDAQ:PTCT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.